Navigation Links
Caprion Biosciences Expands Biomarker Panel Portfolio to Include Predictive Tuberculosis (TB) Infections
Date:7/26/2017

MONTREAL, July 26th, 2017 /PRNewswire/ - Caprion Biosciences Inc., a world leading specialty CRO announced the publication of a novel study identifying host blood proteins predictive of early stage (latent) Mycobacterium tuberculosis (Mtb) infection using state-of-the-art ProteoCarta™, a mass spectrometry (MS) and multiple reaction monitoring (MRM-MS) platform.

Caprion Biosciences Inc. (CNW Group/Caprion Biosciences)
Caprion Biosciences Inc. (CNW Group/Caprion Biosciences)

The new data, recently published in EbioMedicine, expands and strengthens Caprion's existing portfolio of biomarkers assays for predicting and monitoring of active TB, supporting clients who are developing TB therapeutics and diagnostics. "These findings are very significant and could impact the way we approach treatment, providing a solid basis to accelerate the development of predictive testing" said Eustache Paramithiotis, Vice-President of Discovery at Caprion, who led the study in collaboration Charles Bark, MD and W. Henry Boom, MD from Case Western Reserve University.

In this proteomic study, host proteins expressed differentially between patients uninfected and individuals exposed to M. tuberculosis through contact with family members, which were followed over a period of 12 months. Caprion's bioinformatic analysis determined multiple biomarker signatures correlating with subsequent development of an immune response recognizing Mtb. These biomarker signatures may demonstrate individuals recently infected by Mtb at high risk for developing active tuberculosis (TB).  

About Latent M. Tuberculosis Infection (LTBI) and Active TB 
LTBI is a state of persistent immune response resulting from Mtb infection but without evidence of clinically active TB. Current immune-based tests for Mtb infection (LTBI) cannot distinguish recent from remote Mtb infection.  Individuals with recent Mtb infection are at highest risk for developing disease, i.e. TB.  These tests also cannot distinguish LTBI from TB. Worldwide, approximately one-third of the population is latently infected with Mtb, meaning that they do not display any symptoms, chest radiographic abnormalities, or other findings of active TB. Approximately 10% of people with LTBI will develop active TB and are the primary source of TB spreading. Their identification is critical to efforts aimed at controlling TB.

About Caprion Biosciences, Inc.   
Founded in 2000, Caprion is a leading specialty CRO laboratory providing an integrated platform in proteomics and immune monitoring services to the pharmaceutical and biotechnology industry. Caprion's immune monitoring division, ImmuneCarta®, offers proprietary multiparametric flow cytometry services for functional analyses of innate and adaptive immune responses. Caprion's proteomics division, ProteoCarta™, offers proprietary gel-free, label-free MS for comprehensive, quantitative and robust comparative measurement of proteins across large sets of biological samples for the discovery and validation of protein biomarkers. Based in Montreal, Canada, and in Gosselies, Belgium, Caprion has been providing large-scale proteomics and immune monitoring services to over 50 major pharmaceutical and biotech clients for more than 15 years. Caprion, a privately-held company, is majority owned by Global Healthcare Opportunities, or GHO Capital Partners LLP.

For more information, www.caprion.com


'/>"/>
SOURCE Caprion Biosciences
Copyright©2017 PR Newswire.
All rights reserved


Related biology technology :

1. Caprion Biosciences wird Kurzlehrgang und Poster bei Molecular Medicine Tri-Conference in San Francisco präsentieren
2. ACEA Biosciences Announces Successful Completion of Phase I Clinical Study of Novel Autoimmune Disease Drug
3. ACEA Biosciences Announces Collaboration with Memorial Sloan Kettering Cancer Center on Personalized CAR T Cell Therapy
4. Vortex Biosciences Announces Publication in Nature Precision Oncology Describing the Genomic and Phenotypic Characterization of CTCs from Prostate Cancer Patients
5. Therapix Biosciences Announces the Appointment of Josh Blacher as Chief Financial Officer
6. ACEA Biosciences Introduces a Multi-Option Configuration NovoCyte® Flow Cytometer
7. Pendant Biosciences Announces Acceptance into JLABS @ Toronto
8. Cancer and Immunotherapy Symposium Hosted by ACEA Biosciences Gathers Clinicians and Scientists From Around the World
9. TOMA Biosciences Releases the COMPASS Tumor Profiling System
10. Vortex Biosciences Presents Studies at AACR That Demonstrate Use of the VTX-1 System for Isolating and Analyzing Circulating Tumor Cells for Cancer Research
11. Kindred Biosciences to Present at 2017 Jefferies Animal Health Summit
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2019)... ... 22, 2019 , ... Artemis (formerly Agrilyst), the leading enterprise Cultivation ... round co-led by Astanor Ventures and Talis Capital with participation ... iSelect Fund . The company has raised $11.75m to date and will use the ...
(Date:5/15/2019)... Pa. (PRWEB) , ... May 15, 2019 , ... Milton ... Year in recognition for his work within the biomedical industry, where he is changing ... improved medical devices. , “William Harding epitomizes the vision of our founders – ...
(Date:5/14/2019)... ... May 13, 2019 , ... Leak Detection Associates (LDA), ... Pharmaceutical, Biotechnology, Medical Device and Food Packaging Industries’ is excited to announce the ... improve LDA’s ability to communicate directly with the marketplace; serving as a destination ...
(Date:5/8/2019)... , ... May 07, 2019 , ... Standing at 16.2 hands, Atlas is on the ... in a drill team and barrel racing, among other activities. When loping around a ... He went from being a busy horse to only being able to walk. Fortunately ...
Breaking Biology Technology:
(Date:6/18/2019)... , ... June 18, 2019 , ... ... learning cloud solutions, today introduced Data Science Workstations-as-a-Service as part of its dedicated, ... from BOXX Technologies, Cirrascale Data Science Workstations feature NVIDIA® Quadro RTX™ GPUs for ...
(Date:6/16/2019)... , ... June 14, 2019 , ... ... Oracle Cloud customer, will deliver a joint presentation with Versiti’s CIO at the ... 16-19 at the Rosen Shingle Creek Resort. , Versiti Vice President and Chief ...
(Date:6/13/2019)... ... ... KICVentures announced today its plans to host an event at Becker’s 17th ... Chicago on Thursday, June 13th at 6:30 pm. The event will take place at ... Ticino Hospitality room in space #74T. , The event will feature three brief talks ...
Breaking Biology News(10 mins):